Navigation Links
Ambrx Appoints Douglas Axelrod Senior Vice President for Clinical Research and Development
Date:2/26/2008

SAN DIEGO, Feb. 26 /PRNewswire/ -- Ambrx Inc. today announced the appointment of Douglas W. Axelrod, M.D., Ph.D., as Senior Vice President for Clinical Research and Development.

Axelrod joins Ambrx after a productive career spanning nearly two decades at Procter & Gamble Pharmaceuticals. Most recently, he served as Vice President of R&D for Discovery, Early Development and Product Development where he accelerated the discovery process, improved the discovery to early development transition and led efficiencies in product development. Earlier in his career, Axelrod led the P&G Worldwide Clinical Bone group, stewarding drugs such as Didronel(TM) and Actonel(TM) through late clinical development and regulatory approvals. These drugs became among the leading osteoporosis therapies worldwide. Axelrod obtained his doctorate in the Department of Cell Biology at Baylor College of Medicine. He obtained his medical degree at the same institution, where he completed his Residency in Internal Medicine, Fellowship in Endocrinology and Metabolism and served as Visiting Scientist in the Department of Cell Biology at MD Anderson Tumor Institute.

"Doug has tremendous depth and breadth of experience in drug discovery and development and has been successful in delivering innovative medicines to patients," said Steve Kaldor, Ph.D., Ambrx's President and CEO. "He will be integral to the ongoing build out of Ambrx's development capabilities in support of our rapidly maturing pipeline of clinical and preclinical phase protein drug candidates."

Axelrod added: "I am pleased and excited to join Ambrx at this exciting stage of its development. The company has moved rapidly from proof of concept of the ReCODE(TM) technologies to the creation and development of a family of important and practical biologics-based products. I look forward to playing a role in bringing these important products to clinical reality and into the marketplace, both with our collaborators and
'/>"/>

SOURCE Ambrx Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
2. Codexis Appoints Singapore Laboratories Managing Director
3. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
4. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
5. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
6. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
7. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
8. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
9. NeurogesX Appoints New Director to the Board
10. Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs
11. Premier Research Appoints Melissa Jones as Vice President, International Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Global biostimulants market is expected ... an estimated CAGR of 12.5%. In order to ... with least ecological impacts, farmers are looking to ... crop yield more effectively & efficiently. Biostimulants are ... the return on investments. , Leading companies in ...
(Date:11/26/2014)... Boston, MA (PRWEB) November 26, 2014 ... and collaboration company is proud to announce that Darren ... Development and Sales. Darren will drive the ... and positive customer experience. , Darren brings ... He has held key roles in channel operations, from ...
(Date:11/26/2014)... November 26, 2014 2014 Deep ... an in-depth research report on the Global Palmitic ... introduces Palmitic Acid, basic information, including definition, classification, ... and news analysis, etc. , For international ... Palmitic Acid market in China and other ...
(Date:11/26/2014)... , Nov. 25, 2014 Bio-Techne Corporation (NASDAQ: ... appointed Robert Gavin to serve in a ... Protein Platforms Division.  Mr. Gavin will be responsible for ... which includes the ProteinSimple business acquired in July 2014 ... San Jose, California -based ProteinSimple develops and ...
Breaking Biology Technology:2019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 22019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 32019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 4SoundConnect Appoints Director of Channel Development & Sales 2Palmitic Acid Industry Global 2014 Analysis & 2020 Forecasts on Market data, Statics, Development Now at ReportsnReports.com 2Palmitic Acid Industry Global 2014 Analysis & 2020 Forecasts on Market data, Statics, Development Now at ReportsnReports.com 3Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3
... Victhom Human Bionics Inc., "Victhom" (TSX: VHB), today ... at www.victhom.com . The Website features a ... two operating divisions; Neurobionix, which is developing an ... which is developing and manufacturing computerized prostheses for ...
... Endo Pharmaceuticals (Nasdaq: ENDP ) announced today that ... present a corporate update at the J.P. Morgan 27th Annual ... Pacific Time. The conference will be held January 12-15, ... Webcast of the presentation may be accessed on the Endo ...
... Inc. (OTC Bulletin Board: NWBO; AIM: NWBS and NWBT) (the ... class action lawsuit, In re Northwest Biotherapeutics, ... agreed to pay in settlement US$1 million, which is to ... be approved by the Court. Additional details about the ...
Cached Biology Technology:Victhom Announces Launch of Enhanced Company Website 2Endo Pharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference 2Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action 2Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action 3
(Date:11/3/2014)... 2014  NeuroSigma ® , Inc. (NeuroSigma), a ... focused on commercialization of its non-invasive ... of neurological and neuropsychiatric disorders, announced today that ... a Notice of Allowance for Mexican Patent Application ... NeuroSigma and the Regents of the University of ...
(Date:11/2/2014)... , James Dacey explores the ways in which physicists ... innovations from the lab into the commercial market. , ... companies as they move from prototype to product is ... physics-based inventions are usually far from market-ready when initially ... lot more complicated than had been originally thought. , ...
(Date:11/2/2014)... put a flashlight up to our palms to see ... St. Louis engineers are using a similar idea to ... of cancerous tissues and to develop potential treatments. ... Professor of Biomedical Engineering at the School of Engineering ... that allows researchers to better focus light in tissue, ...
Breaking Biology News(10 mins):NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3The 'valley of death' facing physics start-ups 2Improving imaging of cancerous tissues by reversing time 2
... Children,s Research Institute and their collaborators have discovered a ... malformation syndrome that can make it impossible for the ... In a study led by Michael L. Cunningham, MD, ... Center, a research team pinpointed two genes known as ...
... the conditions that zebrafish are kept in could have ... the reliability of results, according to scientists from Queen ... mice, are often used by neuroscientists to explore mechanisms ... to treat behavioural disease such as addiction, attention deficit ...
... Health is seeking to refine and improve lung-cancer screening by ... earlier and more effectively. The trial combines a CT chest ... and seeks to build on recent research demonstrating that CT ... learned that CT screening of high-risk patients can reduce lung-cancer ...
Cached Biology News:Researchers pinpoint genetic pathway of rare facial malformation in children 2Better housing conditions for zebrafish could improve research results 2Better housing conditions for zebrafish could improve research results 3Trial seeks improved lung-cancer screening by combining imaging and biomarkers 2
... powerful solution for all plate washing needs in ... ,The PW 384 provides an excellent solution ... Drug Discovery (Assay development, Screening or Lead Optimization) ... ,The PW 384 has set a standard ...
... Model 1575 immunowash microplate washer, 100-240 V, ... have flat-, U-, or V-bottom wells. This ... needle positions to an accuracy of 0.1 ... overflow washing. It can store up to ...
... a compact benchtop and stackable multi-function ... with a large display screen to ... Air circulation inside to evenly distribute ... be easily calibrated from the microprocessor ...
... MULTI-FUN Incubator is a compact ... uses a microprocessor controller with a ... temperature and agitation speed. Air circulation ... the incubator. Temperature can be easily ...
Biology Products: